Top Markets
#1 TENDIES TENDIES +46.01%
#2 Cash Cat Cash Cat +32.68%
#3 Threshold Network Threshold Network +29.49%
#4 Asteroid Shiba Asteroid Shiba +17.55%
#5 OSK OSK +15.83%
#6 Ape and Pepe Ape and Pepe +12.62%
#7 MarsCoin MarsCoin +11.53%
#8 Kite Kite +9.63%
#9 Ardor Ardor +9.02%
#10 Magma Finance Magma Finance +8.80%
Coin of the day
TENDIES TENDIES
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Oryzon Genomics S.A. Oryzon Genomics S.A.

Oryzon Genomics S.A.

ORY
Kedudukan dalam Saham #16839
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in... Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Harga Saham
$3.31
Disegerakkan terakhir: 2026-09-01
Modal Pasaran
$271.03M
Perubahan (1 hari)
-0.36%
Perubahan (1 tahun)
8.04%
Negara
ES
Perdagangan Oryzon Genomics S.A. (ORY)

Kategori

Healthcare
Nisbah P/E bagi Oryzon Genomics S.A. (ORY)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Oryzon Genomics S.A., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Oryzon Genomics S.A. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.